Ovoca Bio PLC
LSE:OVB
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.55
1.92
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Ovoca Bio PLC
Other Assets
Ovoca Bio PLC
Other Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Ovoca Bio PLC
LSE:OVB
|
Other Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Perrigo Company PLC
NYSE:PRGO
|
Other Assets
$3.4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
0%
|
||
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Other Assets
$1.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
10%
|
||
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Other Assets
$16.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-1%
|
||
G
|
GH Research PLC
NASDAQ:GHRS
|
Other Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Other Assets
€24m
|
CAGR 3-Years
156%
|
CAGR 5-Years
76%
|
CAGR 10-Years
73%
|
Ovoca Bio PLC
Glance View
Ovoca Bio Plc is a clinical-stage biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The firm is engaged in identifying and developing therapeutics targeting the treatment of female sexual dysfunction. The Company’s product BP101 is a synthetic peptide, administered through a nasal spray that is being developed for the treatment of female sexual dysfunction-hypoactive sexual desire disorder (HSDD). The Company’s subsidiaries include Silver Star Ltd, Bulun LLC, Magsel LLC, IVIX LLC and OVB (Australia) Pty Ltd. The firm operates in Ireland, the United Kingdom (UK) and Russia.